Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

Hum Vaccin Immunother. 2022 Nov 30;18(5):2083428. doi: 10.1080/21645515.2022.2083428. Epub 2022 Jun 20.

Abstract

Influenza is a major public health concern causing millions of hospitalizations every year. The current vaccines need annual updating based on prediction of likely strains in the upcoming season. However, mismatches between vaccines and the actual circulating viruses can occur, reducing vaccine effectiveness significantly because of the remarkably high rate of mutation in the viral glycoprotein, hemagglutinin (HA). Clearly, it would be of great interest to determine the potential role of universally conserved epitopes in inducing protective immunity. Here, an antibody against the 14-aa fusion peptide sequence at the N-terminus of the HA2 subunit (Uni-1) was investigated for its ability to elicit antibody-dependent cellular cytotoxicity (ADCC) in vitro and cross-protection against lethal infection in animals. Uni-1, known to neutralize influenza type A (IAV) in vitro, was found to induce strong ADCC against diverse influenza viruses, including human and avian IAVs and both lineages of type B (IBV). The ADCC effects against human IAVs by Uni-1 was comparable to ADCC induced by well-characterized antibodies, F10 and FI6V3. Importantly, mice treated with Uni-1 were protected against lethal challenge of IAV and IBV. These results revealed the versatile effector functions of this universal antibody against markedly diverse strains of both IAV and IBV.

Keywords: Influenza; Uni-1; antibody-dependent cellular cytotoxicity (ADCC); cross-protection; universal antibody.

Plain language summary

The fusion peptide is the only universally conserved epitope in both IAV and IBVMono-specific universal antibody induces strong ADCC against human and avian IAVMono-specific universal antibody induces strong ADCC against IBV from both genetic lineages of IBVThe antibody has bi-functional effector functions against several influenza viruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Humans
  • Influenza Vaccines*
  • Influenza, Human*
  • Mice
  • Orthomyxoviridae Infections*
  • Peptides

Substances

  • Hemagglutinin Glycoproteins, Influenza Virus
  • Antibodies, Viral
  • Influenza Vaccines
  • Peptides

Grants and funding

Xuguang Li reports financial support, administrative support, article publishing charges, equipment, drugs, or supplies, statistical analysis, travel, and writing assistance were provided by Health Canada. Xuguang Li has patent # Reagents and methods for detecting influenza virus proteins (US89 pending to None). Gary Van Domselaar has patent # Reagents and methods for detecting influenza virus proteins (US89 pending to None).